Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 32INDUSTRY 8OTHER_GOV 1NETWORK 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

pembrolizumab 3enzalutamide 3Abiraterone Acetate 3apalutamide 2Topotecan 2Testosterone 2Itraconazole 2Docetaxel 2Cholecalciferol 2Celecoxib 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2zanubrutinib 1venetoclax 1talabostat 1sargramostim 1pasireotide 1olaparib 1leucoselect phytosome 1ibrutinib 1capivasertib 1acalabrutinib 1abiraterone 1Tablets 1Streptozocin 1Rituximab 1Radiosurgery 1Pluvicto 1PT-100 dipeptide 1Oxaliplatin 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × FED × Tablets × Clear all
NCT00086203 2015-03-25

Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

FDA Office of Orphan Products Development

Phase 2 Completed
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡